Biotechnology

Wednesday Feb 15, 2023 - 3:28 pm

InvestorNewsBreaks – MetAlert Inc. (MLRT) Looking to Achieve ‘Big Things’ in 2023

MetAlert (OTC: MLRT) is a pioneer in location-sensitive health monitoring devices and wearable technology products for remote patient monitoring. “MetAlert is looking to achieve ‘some big things’ in 2023. Speaking in an interview with Sequire Spotlight published Dec. 28, CEO Patrick Bertagna outlined the company’s strategic plans for 2023. MetAlert, he explained, is ‘looking at making some acquisitions, bringing on some new products, and possibly…

Wednesday Feb 15, 2023 - 1:27 pm

InvestorNewsBreaks – BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) Lead NanoAb Candidate Demonstrates Significant Advantages

BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, recently achieved key milestones. These include the demonstration of statistically significant positive results from a preclinical in-vivo proof-of-concept study of its inhaled anti-COVID-19 nanosized antibodies (“NanoAbs”). “Its lead NanoAb candidate, designed to treat COVID-19, has exhibited significant competitive advantages over existing…

Wednesday Feb 15, 2023 - 11:37 am

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Receives Confirmation of NASDAQ Compliance

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, has regained compliance with NASDAQ continued listing requirements. The company announced that it has received confirmation from the exchange that it is in compliance with the minimum bid price requirement of $1 per…

Tuesday Feb 14, 2023 - 12:45 pm

InvestorNewsBreaks – IBN to Shine the Spotlight on Health Equity in Clinical Trials Congress

IBN (“InvestorBrandNetwork”), an innovative corporate communications firm and content distributor, today announced its collaboration with Kisaco Research for its upcoming Health Equity in Clinical Trials Congress, which is slated to take place at the beautiful Hilton Boston Back Bay on Feb. 22-23, 2023. Kisaco is a leader in combining state-of-the-art conference production with high-impact networking to drive conversations between marquee organizations, policymakers, academic institutions, medtech…

Tuesday Feb 14, 2023 - 11:01 am

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Forms US-Based Subsidiary with Focus to Expand Innovation Platforms

Aditxt (NASDAQ: ADTX), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announced the formation of a U.S.-based wholly owned subsidiary, Pearsanta Inc. The move intends to accelerate the expansion of Aditxt’s second program, AditxtScore(TM), through future strategic revenue and growth-oriented transactions. According to the update, Anthony Voorhies, currently the head of the AditxtScore(TM) division, will…

Tuesday Feb 14, 2023 - 10:31 am

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Launches New Program Targeting Unmet Medical Needs for Alcohol Misuse

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders. The company today announced the launch of a new research and development program focused on unmet medical needs for alcohol misuse. “Alcohol intoxication is a common presentation in many patients who visit…

Monday Feb 13, 2023 - 11:19 am

InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Files Patent for Treatment of Alzheimer’s

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that it has filed a provisional patent application for the use of its central nervous system (“CNS”) homing peptides to treat Alzheimer’s disease and the onset of dementia. Alzheimer’s has proven to be a progressive neurodegenerative disorder associated with the destruction of higher brain structures, such…

Thursday Feb 09, 2023 - 10:51 am

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Receipt of No Objection Letter from Health Canada Is Focus of Recent InvestmentPitch Media Video

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, has received a No Objection Letter from Health Canada. That letter and what it means was the focus of a recent InvestmentPitch Media video. In the video, InvestmentPitch Media’s Cassandra Bolinski discusses the…

Wednesday Feb 08, 2023 - 2:24 pm

InvestorNewsBreaks – MetAlert Inc. (MLRT) Pushing Boundaries of Innovation

MetAlert (OTC: MLRT), a pioneer in location-sensitive health monitoring devices and wearable technology products, developed GPS SmartSole(R), a medical monitoring device integrated into an orthotic insole, facilitating discreet tracking and remote monitoring of those living with Alzheimer’s, dementia and autism, who have a tendency to wander and become lost. “The SmartSole enables tracking by utilizing a 4G cellular network and … can be configured to…

Wednesday Feb 08, 2023 - 12:43 pm

InvestorNewsBreaks – BioRestorative Therapies Inc. (NASDAQ: BRTX) Eyes Continued Growth of Patent Family for ThermoStem(R) Program

BioRestorative Therapies (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced that the European Patent Office has issued a notice of allowance for a patent application related to the company’s metabolic ThermoStem(R) program. “Our patent family for our ThermoStem program continues to grow as we receive additional patent grants in key markets,” said Lance Alstodt, the company’s CEO. “We are committed…

Wednesday Feb 08, 2023 - 10:37 am

InvestorNewsBreaks – India Globalization Capital Inc. (NYSE American: IGC) to Be Featured in Radius Research Webinar

India Globalization Capital (NYSE American: IGC) today announced that its CEO Ram Mukunda and PFO Claudia Grimaldi will be featured in an investor webinar hosted by Radius Research. Beginning at 12:30 p.m. ET on Friday, Feb. 10, Mukunda and Grimaldi will discuss the company’s phase 2 trial for its drug candidate IGC-AD1 in treating agitation in dementia patients suffering from Alzheimer’s. They will also participate…

Tuesday Feb 07, 2023 - 1:53 pm

InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Partnering to Transform Health Care, Improve Patient Outcomes

Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company, recently provided a progress update on its sponsored clinical trial with the University of California, San Francisco (“UCSF”) examining the effect of psilocybin on inflammation. “Silo’s sponsored clinical trial with the Clinical & Translational Science Institute at UCSF aims to validate the use of psilocybin as a therapeutic by evaluating the effects of the compound on patients…

Tuesday Feb 07, 2023 - 11:37 am

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Receives Health Canada Regulatory Approval to Move Forward with Phase 1 Trial

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, has received notification that it can move forward with its proposed phase 1 clinical trial in Canada. The notification came in the form of a No Objection Letter (“NOL”) from Health Canada. The…

Monday Feb 06, 2023 - 1:54 pm

InvestorNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Animal Study Results Featured in Aegis Capital Corp. Updated Price Target

BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotech company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, is the subject of an updated report released from Aegis Capital Corp. The update reflects the strong results from BVXV’s latest animal study indicating that anti-COVID-19 NanoAb can prevent infection. According to the report, BiondVax reported that in a continuation…

Friday Feb 03, 2023 - 12:34 pm

InvestorNewsBreaks – HeartBeam Inc.’s (NASDAQ: BEAT) Distinctive Solutions Positioned to Transform the Way Patients, Doctors Detect Heart Attacks

HeartBeam (NASDAQ: BEAT) is a cardiac technology company that is leading the way in identifying heart attacks by developing a personal, portable and easy-to-use heart-attack detection solution. “The company has two patented products in development: HeartBeam AIMI(TM), software for acute care settings that provides a 3D comparison of baseline and symptomatic 12-lead ECG to more accurately identify a heart attack, and HeartBeam AIMIGo(TM), the first…

Friday Feb 03, 2023 - 11:51 am

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Pleased with Early Results from Global Clinical Trial

CNS Pharmaceuticals (NASDAQ: CNSP) recently reported that 67 patients have enrolled in the potentially pivotal phase 2 globally cited clinical study comparing drug candidate Berubicin’s effectiveness to second-line standard-of-care chemotherapy drug Lomustine. “The company plans to have more than 200 patients participate in the clinical trial on a 2:1 randomization schema between those receiving Berubicin and those receiving Lomustine… Berubicin’s performance in an initial safety…

Thursday Feb 02, 2023 - 3:06 pm

InvestorNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) to Present at BIO CEO & Investor Conference

BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, today announced that its CEO Amir Reichman will present at the BIO CEO & Investor Conference. The event is slated to take place in New York from Feb. 6-9, 2023. Reichman’s presentation, scheduled to begin at 4:15 p.m. ET on Feb.…

Thursday Feb 02, 2023 - 10:41 am

InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Expands IP Portfolio with New USPTO Patent

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that the U.S. Patent and Trademark Office (“USPTO”) has issued U.S. Patent 11,491,120, titled “Pharmacological Prophylactics Against Stress-Induced Affective Disorders in Females.” The patent’s allowed claims protect the use of portfolio drug SPC-15 in a method of treating stress-induced affective disorders including anxiety and post-traumatic stress…

Thursday Feb 02, 2023 - 9:48 am

InvestorNewsBreaks – Cosmos Health Inc. (NASDAQ: COSM) Begins Process for Upstream Dual Listing

Cosmos Health (NASDAQ: COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, has begun the application process to dual list its shares on Upstream. A trading app for digital securities and NFTs, Upstream is powered by Horizon Fintex and MERJ Exchange Limited. According to the announcement, Cosmos anticipates that the dual listing will provide…

Wednesday Feb 01, 2023 - 1:44 pm

InvestorNewsBreaks – MetAlert Inc. (MLRT) Bringing Quality-of-Life Improvements to Patients and Consumers

MetAlert (OTC: MLRT) is a pioneer in location-sensitive health devices and wearable technology products for remote patient monitoring. The company “has, since inception, sought to offer quality-of-life improvements to patients and consumers who have Alzheimer’s, dementia and autism (‘ADA’)… Its flagship GPS SmartSoles HUB launched in the fourth quarter of the 2022 financial year, allowing for remote monitoring, data collection and encrypted data transmission to…

Wednesday Feb 01, 2023 - 10:59 am

InvestorNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW) Announces Reappointment of Dr. Hector Alila to Establish Advisory Group

Jupiter Wellness (NASDAQ: JUPW), a company focused on hair, skin and sexual wellness, today announced that Dr. Hector Alila has rejoined its board of directors with the specific responsibility of building a technical advisory board. “We are pleased to welcome Hector back to our board. With our focus on new scientific and clinical programs, our immediate need is to build a top-tier team of technical…

Wednesday Feb 01, 2023 - 10:14 am

InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Receives Approval for First-in-Human Dosing of Proprietary DMT Molecule

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has received key approval to initiate human dosing of CYB004, its proprietary deuterated N,N-dimethyltryptamine (“DMT”) molecule, through a protocol amendment to its ongoing CYB004-E phase 1 trial. The approval came from an independent ethics committee in the Netherlands. The first-ever trial that evaluates deuterated DMT in humans, the study is being…

Tuesday Jan 31, 2023 - 10:23 am

InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Board Authorizes Stock Repurchase Program

Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, has announced a stock repurchase program. According to the company, its board of directors has approved the program, which will acquire up to $1 million of the company's common stock. The announcement noted that the company could purchase common stock in a variety of ways, including in the open market…

Monday Jan 30, 2023 - 10:55 am

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Commences Recruitment in FSD201 Phase 2 Clinical Trial

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide. The company today announced that recruiting is underway for its phase 2 trial of FSD201 for the treatment of chronic pain associated with idiopathic MCAS (“MCAD”) at two clinical sites in the USA, with a Canadian…

Thursday Jan 26, 2023 - 1:40 pm

InvestorNewsBreaks – MetAlert Inc.’s (MLRT) Acquisition Target’s SafetyNet(R) Featured in New Article

MetAlert (OTC: MLRT), a leading solution provider for consumers/patients afflicted with movement, cognitive and spatial awareness disorders, recently announced that it offered $4.5 million in a cash and stock deal to acquire TrakTec LLC. Offering affordable, scalable location-awareness technology solutions, TrakTec made the news in a new Fairmont Post article that discusses its SafetyNet(R) service and others like it that are providing peace of mind…

Thursday Jan 26, 2023 - 11:30 am

InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Virtual R&D Day

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has scheduled a virtual R&D Day for Feb. 28, 2023; the event is scheduled from 10 to 11:30 a.m. ET. The Cybin leadership team is slated to host the event, which will include an update on the company’s development pipeline of differentiated psychedelic-based therapeutics, including CYB003, which is being evaluated for…

Wednesday Jan 25, 2023 - 12:54 pm

InvestorNewsBreaks – India Globalization Capital Inc. (NYSE American: IGC) Advances Novel Drug Candidate in Treating Alzheimer’s Symptoms

India Globalization Capital (NYSE American: IGC), in a historic first, has begun phase 2 clinical trials evaluating its flagship drug candidate, IGC-AD1, for the treatment of agitation in dementia from Alzheimer’s disease. “Company officials noted that, to their knowledge, this is the first natural low-dose THC-based compound to enter human trials for the treatment of symptoms such as agitation in dementia from Alzheimer’s disease. Currently…

Wednesday Jan 25, 2023 - 11:24 am

InvestorNewsBreaks – MetAlert Inc. (MLRT) Announces Launch of Its Next-Gen SmartSole in Sweden

MetAlert (OTC: MLRT) today announced the launch of its new 4G GPS SmartSole in Sweden through its distribution partner Posifon AB. The upgraded GPS SmartSole introduction will be an important part of the national service agreement Posifon recently secured with major municipalities across Sweden related to providing home care, personal tracking and security for seniors. Initial shipments of the GPS SmartSole will be distributed to…

Wednesday Jan 25, 2023 - 9:55 am

InvestorNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW) $4.1M Placements Supported by Aegis Capital Corp. as Exclusive Placement Agent

Jupiter Wellness (NASDAQ: JUPW), a company focused on hair, skin and sexual wellness, recently announced the closing of both a registered direct and a private placement; the placements totaled approximately $4.1 million. Aegis Capital Corp. acted as exclusive placement agent for those placements. In the wealth management and investment banking business since 1984, Aegis has built a reputation for offering corporate finance and strategic advisory…

Tuesday Jan 24, 2023 - 11:58 am

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Discusses ‘Lifeblood’ of Phase 2 Berubicin Trial

CNS Pharmaceuticals (NASDAQ: CNSP), a clinical-stage biopharmaceutical company focused on developing novel treatments for primary and metastatic cancers in the brain and central nervous system, is enrolling patients in a phase 2 trial to evaluate the efficacy of its flagship drug candidate. The potentially pivotal trial will evaluate Berubicin for the treatment of glioblastoma multiforme (“GBM”), an aggressive brain tumor with an average overall survival…

Tuesday Jan 24, 2023 - 11:33 am

InvestorNewsBreaks – MetAlert Inc. (MLRT) Approaching Inflection Point of Its Growth Curve

MetAlert (OTC: MLRT), a pioneer in location-sensitive health monitoring devices and wearable technology products for remote patient monitoring, is launching a suite of wearable companion products to its innovative SmartSole shoe insole units. “The patented GPS-enabled SmartSole is a non-intrusive tracking device designed to monitor the location of people with cognitive memory disorders such as Alzheimer’s Disease who tend to get lost or wander. The…

Tuesday Jan 24, 2023 - 10:46 am

InvestorNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Names Senior Medical Tech Veteran as New President

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (“VECG”) platform for heart attack detection anytime, anywhere, has appointed Robert Eno to the newly created position of president. A senior medical technology executive, Eno will work to enhance the company’s strategic and operations capabilities. Eno brings a background of almost three decades experience in developing markets and commercializing…

Tuesday Jan 24, 2023 - 9:55 am

InvestorNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW) Closes on $4.1M Direct, Private Placement Offerings

Jupiter Wellness (NASDAQ: JUPW), a wellness company focused on hair, skin and sexual wellness, has closed on its previously announced registered direct offering and concurrent private placement. The offering includes the purchase and sale of 4,315,787 shares in a registered direct offering, with the concurrent private placement calling for JUPW to issue and sell a total of 8,631,574 warrants to the same investors. The warrants…

Monday Jan 23, 2023 - 12:00 pm

InvestorNewsBreaks – Jupiter Wellness Inc.’s (NASDAQ: JUPW) Redeemable Digital Coupons Now Available for Shareholders of Record

Jupiter Wellness (NASDAQ: JUPW), a company focused on hair, skin and sexual wellness, today announced availability of its redeemable digital coupons for shareholders of record to claim on Upstream’s trading app. Upon successful claim, shareholders may redeem the digital coupon for a gift package of company products valued at over $179 or trade with others globally on Upstream to bring new potential customers into the…

Monday Jan 23, 2023 - 11:42 am

InvestorNewsBreaks – QSAM Biosciences Inc. (QSAM) to Present at Emerging Growth Conference

QSAM Biosciences (OTCQB: QSAM) is developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam(R)), for the treatment of bone cancer and related diseases and conditions. The company today announced that it has been invited to present at the Emerging Growth Conference at 10:15 a.m. ET on Wednesday, Jan. 25, 2023. Leading QSAM’s presentation will be the company’s CEO Douglas Baum and other executive officers, who may subsequently…

Monday Jan 23, 2023 - 10:44 am

InvestorNewsBreaks – BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) NanoAb May Serve as Therapeutic and Prophylactic as Shown in Preclinical Study

BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, today announced additional results in a preclinical proof-of-concept study of its innovative inhaled NanoAb COVID-19 drug. According to the update, the study used an industry-standard animal model to compare weight loss in two groups of hamsters. Hamsters administered a mid-sized 0.66mg…

Friday Jan 20, 2023 - 12:26 pm

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Reaches Pivotal Milestone to Advance ADI (TM) Technology

Aditxt (NASDAQ: ADTX) recently announced the formation of a U.S.-based wholly owned subsidiary, Adimune Inc., and appointed Joachim-Friedrich Kapp, MD, Ph.D, a 30-year veteran of the pharmaceutical industry, as its chairman and CEO. “Dr. Kapp will be tasked with leading and developing the ADI(TM) immune modulation technology and ADI(TM)-100, Aditxt’s unique and potent antigen-specific immunotherapeutic technology drug candidate, toward clinical trials… Short for Apoptotic DNA…

Friday Jan 20, 2023 - 12:11 pm

InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Eying Broad Market Opportunities for Its Liposomal Joint Homing Peptide

Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, recently revealed positive interim data from its dose optimization study of SPU-21 joint homing peptides for subcutaneous administration of anti-arthritic agents. “Silo Pharma provided an update on the ongoing study as of Dec. 30, 2022. During the study, tests were conducted to evaluate the disease-suppressive effects of an SPU-21…

Friday Jan 20, 2023 - 10:56 am

InvestorNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW) Issues Correction Regarding $4.1M Registered Direct and Private Placement

Jupiter Wellness (NASDAQ: JUPW), a company focused on hair, skin and sexual wellness, on Thursday announced its entry into a definitive agreement with investors in a registered direct offering, as well as details surrounding a concurrent private placement. The company issued an update to the initial release to correct the final share count and closing date. The registered direct offering is for the purchase and…

Thursday Jan 19, 2023 - 12:52 pm

InvestorNewsBreaks – HeartBeam Inc.’s (NASDAQ: BEAT) Growing Patent Portfolio Poised to Have Disruptive Effect on Multibillion Markets

HeartBeam (NASDAQ: BEAT), a cardiac technology company with a track record for innovation and cutting-edge technology, recently announced that it was granted a patent for its 12-lead electrocardiogram (“ECG”) smartwatch-based monitor designed to identify heart attacks and complex cardiac arrhythmias. “The breakthrough inventions protected by this patent enable our proprietary 3D ECG technology to be built into a smartwatch, eliminating the need for a dedicated…

InvestorNewsBreaks

NewsBreak Category: Biotechnology

Get Started with InvestorWire

Press Distribution

Explore Press Distribution Solutions

Discover Add-on Solutions